Search results
The Dyne Therapeutics Inc (DYN) Company: A Short SWOT Analysis
GuruFocus.com via Yahoo Finance· 7 months agoDyne Therapeutics Inc's innovative FORCE platform presents a unique strength in the biotech...
All You Need to Know About Dyne Therapeutics, Inc. (DYN) Rating Upgrade to Strong Buy
Zacks via Yahoo Finance· 1 year agoDyne Therapeutics, Inc. (DYN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing...
Dyne Therapeutics Inc (DYN) Reports Q3 2023 Financial Results and Progress in Clinical Trials
GuruFocus.com via Yahoo Finance· 7 months agoDyne Therapeutics Inc (NASDAQ:DYN) reported a net loss of $60.2 million for Q3 2023, compared to a...
Institutional owners may ignore Dyne Therapeutics, Inc.'s (NASDAQ:DYN) recent US$56m market cap...
Simply Wall St. via Yahoo Finance· 4 months agoKey Insights Institutions' substantial holdings in Dyne Therapeutics implies that they have...
CEO & President Joshua Brumm Sells 100,000 Shares of Dyne Therapeutics Inc (DYN)
GuruFocus.com via Yahoo Finance· 2 months agoJoshua Brumm, CEO & President of Dyne Therapeutics Inc (NASDAQ:DYN), has sold 100,000 shares of the...
Here's Why Dyne Therapeutics, Inc. (DYN) Is a Great 'Buy the Bottom' Stock Now
Zacks via Yahoo Finance· 1 year agoDyne Therapeutics, Inc. (DYN) appears to have found support after losing some value lately, as...
Insider Sell: Chief Medical Officer Wildon Farwell Sells 1,707 Shares of Dyne Therapeutics Inc
GuruFocus.com via Yahoo Finance· 8 months agoOn September 12, 2023, Wildon Farwell, the Chief Medical Officer of Dyne Therapeutics Inc...
Does Dyne Therapeutics, Inc. (DYN) Have the Potential to Rally 84% as Wall Street Analysts Expect?
Zacks via Yahoo Finance· 1 year agoThe average of price targets set by Wall Street analysts indicates a potential upside of 84% in Dyne...
Dyne Therapeutics Inc (DYN) Reports Encouraging Clinical Data and Financial Growth for Q4 and ...
GuruFocus.com via Yahoo Finance· 2 months agoCash Position: $123.1 million as of December 31, 2023, with a projected cash runway through 2025. R&D Expenses: Increased to $58.8 million in Q4 2023 from $33.2 million in Q4 2022. G&A Expenses ...
We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully
Simply Wall St. via Yahoo Finance· 7 months agoJust because a business does not make any money, does not mean that the stock will go down. For...